NCT01597947

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Achaogen, Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, and PK of ACHN-975 in normal healthy volunteers. This study will take place in the US at one clinical site.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ACHN-975	Intravenous single dose
DRUG	placebo	Intravenous single dose

Timeline

• Start date: 2012-05-01
• Completion: 2012-12-01
• First posted: 2012-05-15
• Last updated: 2013-01-21

Locations

1 site across 1 country: United States